Kyle Doherty

Articles

Enzalutamide Receives Go Ahead From European Commission in nmHSPC

April 24th 2024

The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.

New Prostate Cancer Urine Test Produces Greater Diagnostic Accuracy vs Existing Tests in High-Grade Prostate Cancer

April 23rd 2024

The MyProstateScore 2.0 urine test led to greater diagnostic accuracy for high-grade prostate cancer compared with existing biomarker tests.

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Functional Precision Medicine Method Aids Treatment Decision-Making in R/R Pediatric Cancers

April 19th 2024

A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024

Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

April 18th 2024

Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.

ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes

April 17th 2024

The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.

Immunotherapy-Based Approaches Make Waves in Bladder Cancer

April 17th 2024

Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more.

B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL

April 17th 2024

B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.

Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies

April 15th 2024

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.

NICE Recommends Tisagenlecleucel for Pediatric R/R B-ALL

April 11th 2024

The National Institute for Health and Care Excellence has recommended the use of tisagenlecleucel in pediatric B-cell acute lymphoblastic leukemia.

Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis

April 11th 2024

Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.

CAN-2409 Receives FDA Orphan Drug Designation in Pancreatic Cancer

April 11th 2024

CAN-2409 has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma

April 10th 2024

The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.

Global Cancer Statistics Report Provides Insights into Cancer Incidence and Mortality

April 10th 2024

The Global Cancer Statistics, 2024, report from the American Cancer Society sheds light on worldwide cancer facts, identifying trends and making predictions for the future.

Breast-Conserving Therapy Bests Mastectomy After Preoperative Systemic Therapy in HER2+ Breast Cancer

April 9th 2024

Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.

Copanlisib Plus Nivolumab Demonstrates Activity in Microsatellite Stable Colorectal Cancer

April 8th 2024

Copanlisib plus nivolumab was active and met the primary end point of a phase 1/2 study in a cohort of patients with MSS CRC.

Afamitresgene Autoleucel Demonstrates Efficacy in Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

April 5th 2024

Afami-cel displayed activity in a heavily pretreated population of patients with advanced synovial sarcoma or myxoid round cell liposarcoma.

Tiwari Highlights Updates in HER2+ and HER2-Low Breast Cancer

April 4th 2024

Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.

Tripathy Outlines Where the HER2+ Early-Stage Breast Cancer Landscape Stands

April 3rd 2024

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.